BPC-157: what the research literature shows

What it is

Origin and name

BPC stands for “body protection compound”.³ A 1993 overview from the Department of Pharmacology at the University of Zagreb described a newly isolated gastric juice peptide with a relative molecular mass of 40,000, named BPC, and a 15-amino-acid fragment of it, BPC 157, which the authors had characterized and tested.² Later papers from the same group also use the codes PL-10, PLD-116 and PL 14736.¹¹

Authors describe its origin differently. A systematic review calls it a naturally occurring gastric peptide,¹² and a pharmaceutics review calls it a synthetic peptide derived from a fragment of a gastric protein.⁴ A group in China reports having set up a solid-phase synthesis process for it.¹³

Sequence and chemistry

The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, or GEPPPGKPADDAGLV in one-letter code.¹⁴ PubChem gives the formula C62H98N16O22, a molecular weight of 1419.5 g/mol and the CAS number 137525-51-0.¹

Four of the 15 residues are proline. Three side chains are acidic and one is basic, so the peptide carries a net negative charge at neutral pH. The sequence has no cysteine, methionine or tryptophan, residues that are prone to oxidation, and no asparagine or glutamine, residues that can deamidate.¹ The guide to how peptides degrade explains why those residues matter.

Cell study A sports drug-testing laboratory in the United States incubated the peptide in plasma and reported that it formed a stable metabolite; in a separate test the peptide was stable in urine for at least four days.¹⁴

How it is studied

Three kinds of experiment recur in the literature.

• Surgical injury in rodents. A tendon, ligament or muscle is cut or crushed, or a piece of bowel is cut and rejoined.^11151617 Treated animals are compared with controls on load to failure, functional scores and histology.¹⁵¹⁸
• Chemical and vascular injury in rodents. Ulcers are induced with an irritant or a drug, or the blood supply to a limb is interrupted, and lesion severity, blood-flow recovery and tissue markers are recorded.¹⁹²⁰
• Cell and tissue assays. Fibroblasts from tendon and cultured endothelial cells are tested for migration, survival under stress, tube formation and protein phosphorylation.²⁰²¹

All of this sits on the lower rungs of the evidence ladder, which the guide to levels of evidence in peptide research explains.

Who has published the work

The literature is unusually concentrated. On 8 October 2026 a PubMed search for “BPC 157” or “BPC157” in titles and abstracts returned 226 records, and 174 of them, about three in four, list P. Sikiric of the University of Zagreb as an author.⁶ A 2019 review of the soft-tissue studies had already noted that only a handful of groups had studied the peptide in depth over two decades.³

Groups in Taiwan, China and Türkiye have also run cell and animal studies.¹⁸¹⁹²¹

What the literature reports

Tendon and ligament

Animal study The Zagreb group cut the Achilles tendon in rats, leaving a gap between the ends, and followed the animals for 14 days.¹⁵ It reported a higher load to failure, higher scores on a functional index and greater collagen formation in treated rats than in saline controls.¹⁵

Animal study The same group cut the medial collateral ligament in rats and reported functional, biomechanical and histological differences in favour of treated animals over 90 days.¹⁶

Cell study At Chang Gung University in Taiwan, fibroblasts grew out of rat tendon explants faster with the peptide in the medium, survived hydrogen peroxide stress in greater numbers and migrated more in a filter assay, while their rate of proliferation did not change.²¹ Phosphorylation of two adhesion proteins, FAK and paxillin, increased.²¹

Animal study In a 2026 study from Türkiye, 32 rats had the Achilles tendon cut and repaired and were randomly assigned to control, BPC-157, TB-500 or both peptides, with tendons examined at four weeks.¹⁸ Load to failure was higher than control in both single-peptide groups, but the difference was statistically significant only for TB-500.¹⁸ Total histology scores in the BPC-157 group were numerically better than control but not significantly so, the two peptides together added nothing over either alone, and the authors called the study exploratory.¹⁸

Skeletal muscle

Animal study After a crush injury to the gastrocnemius muscle in rats, the Zagreb group reported less hematoma and edema, better function and more favourable enzyme measures such as creatine kinase in treated animals over 14 days.¹⁷

Review A 2025 systematic review of the musculoskeletal literature included 36 studies, 35 of them preclinical.¹² It concluded that functional, structural and biomechanical outcomes were better in treated animals across muscle, tendon, ligament and bone models, and it described the included work as level IV and level V evidence.¹²

Gut

Animal study In a rat model in which the small bowel was cut and rejoined, the Zagreb group reported that the join in treated animals held higher pressure before leaking, with less edema and more granulation tissue and collagen over 14 days.¹¹

Animal study A group in Nanjing induced gastric ulcers in rats and, once those ulcers had healed, gave clopidogrel, a drug that made them recur.¹⁹ Rats that also received BPC 157 had less mucosal damage, and blocking nitric oxide synthesis weakened the difference.¹⁹

Blood vessels and blood flow

Cell study A later paper from the same institute at Chang Gung University reported more tube formation in an endothelial cell assay and, in human vascular endothelial cells, higher expression of the receptor VEGFR2 but not of the growth factor VEGF-A, with activation of a VEGFR2-Akt-eNOS signalling pathway.²⁰

Animal study In the same paper, vessel density rose in a chick embryo membrane assay, and rats with an ischemic hind limb recovered blood flow faster on laser Doppler imaging and had more vessels in the muscle.²⁰

Review A 2026 critical review of rodent ischemia-reperfusion studies found reports of less oxidative injury and altered nitric-oxide-related vascular responses in limb, brain, gut and liver models.⁵ It judged the evidence heterogeneous, often limited to short observation periods and incompletely reported on risk of bias, and it called for independent blinded replication and controlled human studies before any clinical conclusion.⁵

Disposition and safety in animals

Animal study In a pharmacokinetic study in rats and beagle dogs, the intact peptide had an elimination half-life of less than 30 minutes, and radiolabelled peptide was broken down quickly into small fragments and single amino acids and excreted in urine and bile.¹³

Review The 2025 systematic review found that preclinical safety studies reported no adverse effects across several organ systems, and it found no clinical safety data.¹²

Human evidence

There is very little human evidence.

Review A 2026 review found clinical data from three uncontrolled pilot studies only, none of which used a standardized pharmaceutical preparation, and no completed Phase II trial.⁴ All three have the same first author and appeared in the same journal.⁷⁸⁹

Human study The first was a chart review at one clinic of patients who had received BPC-157 for knee pain: 16 were reached by telephone months later and 14 said the pain had eased.⁷ No specific tool was used to measure function, and four of the 16 had also received thymosin beta-4.⁷

Human study The second reported on 12 women with interstitial cystitis who received the peptide in one procedure at a private clinic; the outcome was each patient’s own rating, and no adverse events were reported.⁸

Human study The third followed blood tests and vital signs in two adults over three days and reported no adverse effects; both had received the peptide before the study.⁹

On 8 October 2026 a PubMed search for “BPC 157” or “BPC157” in titles and abstracts returned no record indexed as a clinical trial.⁶ A 2007 Zagreb paper refers to clinical trials for inflammatory bowel disease;¹¹ the search returned no clinical-trial report of them.⁶

Small uncontrolled reports that rely on patients’ own ratings cannot show whether a compound has an effect in people, or whether it is safe.

Regulatory status

Each statement below was checked against the cited page on 8 October 2026.

• Canada. A search of Health Canada’s Drug Product Database for BPC-157 as an active ingredient returned no product.¹⁰ In a public advisory dated 9 April 2026, Health Canada named BPC-157 among examples of unauthorized peptide drugs it had seized.²³ It said that such products have not been assessed for safety, efficacy and quality, and that a “For Research Use Only” label does not make them legal or exempt them from regulatory requirements.²³
• United States. A search of the FDA’s approved-drug data for BPC-157 as an active ingredient returned no match.²⁴ The FDA lists BPC-157 among bulk drug substances that were in category 2 of its interim compounding policies, the category for substances that may present significant safety risks, until their nominators withdrew them.²⁵ Its entry cites a possible risk of immunogenicity, peptide-related impurities and no or only limited safety information.²⁵
• Sport. The U.S. Anti-Doping Agency states that BPC-157 is prohibited under category S0, non-approved substances, of the World Anti-Doping Agency Prohibited List.²⁶
• Registered trials. A ClinicalTrials.gov search for BPC-157 listed four studies: a Phase 1 study in healthy volunteers registered in 2015, status unknown; a completed single-group study of a supplement product; a Phase 2 placebo-controlled trial in hamstring strain, recruiting; and a Phase 1 study in rotator cuff repair, not yet recruiting.²² None had posted results.²²

Horizon Peptides supplies BPC-157 for laboratory research use only.

In the laboratory

Horizon supplies BPC-157 as a lyophilized powder in sealed vials; see the BPC-157 vial.

Review A 2026 pharmaceutics review found that no formulation of the peptide has been developed or validated to a pharmaceutical standard, and that formal excipient-compatibility studies are missing.⁴

The guide to analytical methods for peptides explains how a purity trace by HPLC and a mass spectrum are read; for BPC-157 the spectrum is compared with the formula C62H98N16O22.¹ Batch documents are published on the Lab Results page when they exist.

General rules for keeping dry peptide are in the peptide storage guide. A PubMed search on 8 October 2026 that combined the peptide’s name with shelf-life and storage-stability terms returned no records.⁶